clinical trial · NCT07648914
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
Sichuan Baili Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 446
Breast CancerBL-B01D1Albumin-Bound PaclitaxelPaclitaxelCapecitabine
brief summary
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer after failure of prior endocrine therapy.
started
Jun 1, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Jul 10, 2026
detailed description
In this trial, the experimental group receives BL-B01D1, and the control group receives chemotherapy of physician's choice.
official title
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol